The Company’s has IPR covering the NK-cell based drug candidate CellProtect through two granted patents priority dates during 2007 and 2009 respectively. The IP covers key elements of the manufacturing process as well as the expanded NK-cells and the use of the NK-cell product. The patents are designated for the major markets and have been granted in US, China, Hong Kong, EU and Korea.
The company has an active patent strategy and a new “method of use” patent application was submitted in 2018.
In addition to the IP protection, CellProtect Nordic Pharmaceuticals AB also holds extensive and in-depth know-how in the field of cell therapies and GMP manufacturing processes.